First phase viral kinetic parameters and prediction of response to interferon alpha-2b/ribavirin combination therapy in patients with chronic hepatitis C.

First phase viral kinetic parameters and prediction of response to interferon alpha-2b/ribavirin combination therapy in patients with chronic hepatitis C. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

First phase viral kinetic parameters and prediction of response to interferon alpha-2b/ribavirin combination therapy in patients with chronic hepatitis C. Abstract Text:

Akiko Makiyama,Yoshito Itoh,Kohichiroh Yasui,Kohjiroh Mori,Mika Okita,Mika Nakayama,Junko Yamaoka,Masahito Minami,Tomoki Nakajima,Takeshi Okanoue,

The aim of the present study was to assess parameters in early phase HCV dynamics for predicting the outcome of interferon (IFN)/ribavirin combination therapy in patients with chronic hepatitis C (CH-C). Sixty-five CH-C patients who received IFN alpha-2b/ribavirin combination therapy were enrolled. The serum levels of HCV RNA 0h and 3 months after commencing therapy were serially quantified. HCV kinetic parameters such as quantity, ratio of decline, and half-life were analyzed. In genotype 1 patients, both the quantity and the ratio of decline of HCV RNA 24h after the start of therapy were useful predictors of a poor response. No patients who had serum HCV RNA above 200KIU/ml 24h after the start of therapy achieved a sustained viral response (SVR). In genotype 2 patients, conversely, these two parameters were predictors of a sustained viral response. The efficacy of these parameters in predicting the outcome of therapy was comparable to that of the disappearance of HCV RNA from sera at 4 weeks. These results demonstrate that parameters of HCV kinetics 24h after the start of therapy are useful for the early prediction of outcome in response to IFN alpha-2b/ribavirin combination therapy.

First phase viral kinetic parameters and prediction of response to interferon alpha-2b/ribavirin combination therapy in patients with chronic hepatitis C. Publishing Authors By Initials

A Makiyama,Y Itoh,K Yasui,K Mori,M Okita,M Nakayama,J Yamaoka,M Minami,T Nakajima,T Okanoue,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

First phase viral kinetic parameters and prediction of response to interferon alpha-2b/ribavirin combination therapy in patients with chronic hepatitis C. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Hepatology research : the official journal of the

VOLUME: 36

Page Numbers: 94-9

Journal Abbreviation: Hepatol. Res.

ISSN: 1386-6346

DAY: 6

MONTH: 09

YEAR: 2006

First phase viral kinetic parameters and prediction of response to interferon alpha-2b/ribavirin combination therapy in patients with chronic hepatitis C. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9711801

First phase viral kinetic parameters and prediction of response to interferon alpha-2b/ribavirin combination therapy in patients with chronic hepatitis C. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: First phase viral kinetic parameters and prediction of response to interferon alpha-2b/ribavirin combination therapy in patients with chronic hepatitis C. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for First phase viral kinetic parameters and prediction of response to interferon alpha-2b/ribavirin combination therapy in patients with chronic hepatitis C.

AFFILIATION: Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kawaramachi-Hirokouji, Kamigyou-ku, Kyoto 602-8566, Japan.

Country: Netherlands

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Hepatol Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

First phase viral kinetic parameters and prediction of response to interferon alpha-2b/ribavirin combination therapy in patients with chronic hepatitis C Related Publications

• A case of adult-onset type II citrullinemia having a liver histology of nonalcoholic steatohepatitis (NASH).
• Activation of B-Myb by E2F1 in hepatocellular carcinoma.
• CREB3L4, INTS3, and SNAPAP are targets for the 1q21 amplicon frequently detected in hepatocellular carcinoma.
• Clinicopathological characteristics of esophageal squamous papillomas in Japanese patients-with comparison of findings from Western countries.
• Effect of iron reduction by phlebotomy in Japanese patients with nonalcoholic steatohepatitis: A pilot study.
• Elevation of serum thioredoxin levels in patients with nonalcoholic steatohepatitis.
• Evidence of oxidative stress as a cofactor in the development of insulin resistance in patients with chronic hepatitis C.
• First phase viral kinetic parameters and prediction of response to interferon alpha-2b/ribavirin combination therapy in patients with chronic hepatitis C.
• Management of HBV infection in Japan.
• Molecular mechanisms involved in interleukin-8 production by normal human oesophageal epithelial cells.
• Preface.
• Review article: anti-tryptase therapy in inflammatory bowel disease.
• The severity of ultrasonographic findings in nonalcoholic Fatty liver disease reflects the metabolic syndrome and visceral fat accumulation.
• [Indication of antiviral therapy for chronic hepatitis B]